Biomay's Pipeline for Immunotherapy of Allergic Diseases

Biomay has assembled an impressive pipeline of innovative products for immunotherapy of allergic diseases based on its proprietary technology platforms.

The IgE immune apheresis device IgEnio®, co-developed with Fresenius Medical Care, has achieved CE mark designation and is currently actively marketed in several European countries. Additional clinical studies are underway to broaden the scope of applications for this unique product.

The most advanced peptide carrier fusion allergy vaccine BM32, indicated for grass pollen allergy, has completed phase IIb of clinical development and is ready for phase III pivotal Trials.